Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:4 Issue:3 Number:116 ISSN#:2563-5476
ACE Report #8433
Ace Report Cover Metabolic Disorders

Combined parathyroid hormone+alendronate therapy versus PTH monotherpy for osteoporosis

Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A

Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

J Invest Surg. 2015 Dec;28(6):309-16

Contributing Authors: C Wang G Zhang G Mingyong J Fan J Chen B Li

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


6 randomized controlled trials, including a total of 833 patients, were analyzed to evaluate the efficacy of combined parathyroid hormone (PTH) and alendronate administration in the treatment of osteoporosis. The meta-analysis assessed mean percent increases in bone mineral density (BMD) at the lumbar spine, femoral neck, total hip, and distal radius with combination therapy compared to monothera...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.